Versions
- November 18, 2022 (2)
- October 20, 2022 (1)
Supplementary Files
How to Cite
Abstract
El dolor neuropático surge de una lesión nerviosa que altera principalmente el sistema somato sensorial. Al producirse un daño en un nervio, se generan descargas continuas de las neuronas nociceptivas que conducen a un estado de hiperexcitabilidad el cual se constata por un incremento de la actividad espontánea, una reducción del umbral de excitación y una ampliación de receptividad para otros estímulos de naturaleza no dolorosa. Este dolor se caracteriza por ser una sensación intensa, quemante y de carácter crónico. Actualmente, los antidepresivos tricíclicos y los inhibidores duales de la recaptura de serotonina y norepinefrina se encuentran en la primera línea de tratamiento. Sin embargo, estos tienen una eficacia modesta y, a menudo, causan efectos adversos molestos como mareos, náuseas, somnolencia y dolor de cabeza. Ante la alta prevalencia de este tipo de dolor y su impacto, se realiza la presente revisión bibliográfica la cual mediante una búsqueda sistematizada identificó los principales artículos de revisión relacionados en el periodo comprendido del 2015 al 2021 y proporciona los aspectos fundamentales de la patogénesis para una mejor comprensión del mecanismo de acción de los medicamentos utilizados en el tratamiento de este tipo de dolor. Así como otras posibles dianas terapéuticas, principales relaciones de la estructura química con la actividad biológica de los antidepresivos y terapias en investigación para el abordaje del dolor neuropático.
Palabras clave: Dolor Neuropático, Patogénesis, Tratamiento, Antidepresivos, Relaciones Estructura Actividad. Fuente:DeCS/MeSH.
References
Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008 Apr 29;70(18):1630–1635.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D et al. Neuropathic pain. Nature Reviews Disease Primers. 2017 Feb 16;3:17002.
Khangura RK, Sharma J, Bali A, Singh N, Singh Jaggi A. An integrated review on new targets in the treatment of neuropathic pain. Korean J Physiol Pharmacol. 2019 Ene 1;23(1):1–20.
Yan Y, Li C, Zhou L, Ao L, Fang W, Li Y. Research progress of mechanisms and drug therapy for neuropathic pain. Life Sciences. 2017 Dic 1;190:68–77.
Correa G. Dolor neuropático, clasificación y estrategias de manejo para médicos generales. Revista Médica Clínica Las Condes. 2014;25(2):189–199.
Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice ASC et al. A new definition of neuropathic pain. Pain. 2011 Oct;152(10):2204–2205.
Bouhassira D. Neuropathic pain: Definition, assessment, and epidemiology. Rev Neurol (Paris). 2019;175(1–2):16–25.
Finnerup NB, Haroutounian S, Baron R, Dworkin RH, Gilron I, Haanpaa M, et al. Neuropathic pain clinical trials: Factors associated with decreases in estimated drug efficacy. Pain. 2018;159(11):2339–2346.
Bannister K, Sachau J, Baron R, Dickenson AH. Neuropathic pain: Mechanism-based therapeutics. Annu Rev Pharmacol Toxicol. 2020 Ene 6;60:257–274.
Nurmikko T. Pathophysiology and treatment of neuropathic pain. Therapeutic Research. 1994;15(12):463–466.
Carvajal AMR, Osorio CAO, Rojas SM, Bernal I. Recomendaciones basadas en la evidencia para el manejo del dolor neuropático (revisión de la literatura). Revista de la Sociedad Española del Dolor. 2018;25(6):349–358.
Balzani E, Fanelli A, Malafoglia V, Tenti M, Ilari S, Corraro A et al. A Review of the Clinical and Therapeutic Implications of Neuropathic Pain. Biomedicines. 2021 Set 16;9(9):1239.
Bendaña JE. Dolor neuropático: actualización en definiciones y su tratamiento farmacológico. Revista Médica Hondureña. 2020 Jun 30;88(1):48–51.
Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI et al. The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain. 2019 Jan 1;160(1):53–59.
Alcántara Montero A, Ibor Vidal PJ, Alonso Verdugo A, Trillo Calvo E. Actualización en el tratamiento farmacológico del dolor neuropático. Medicina de Familia Semergen. 2019 Nov 1;45(8):535–545.
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009 Jun;32:1–32.
Bohlega S, Alsaadi T, Amir A, Hosny H, Karawagh AM, Moulin D et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle east region. J Int Med Res. 2010;38(2):295–317.
Finnerup NB, Attal N. Pharmacotherapy of neuropathic pain: time to rewrite the rulebook? Vol. 6, Pain management. 2016. p. 1–3.
Foye W, Lemke T, Williams D, Roche V, Zito W. Foye’s Principles of Medical Chemistry. 7th ed. Lemke T, Williams D, Roche V, Zito W, editors. Foye’s Principles of Medical Chemistry. Philadelphia: Wolters Kluwer; 2013.
Velasco M. Dolor neuropático. Revista Médica Clínica Las Condes. 2014 Jul;25(4):625–634.
Gruener H, Zeilig G, Laufer Y, Blumen N, Defrin R. Differential pain modulation properties in central neuropathic pain after spinal cord injury. Pain. 2016 Jul 1;157(7):1415–1424.
Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmocol. 2019;33.
John Smith E. Advances in understanding nociception and neuropathic pain. J Neurol. 2018;265(2):231–238.
Van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain. 2014 Abr;155(4):654–662.
Hwang S, van Nooten F, Wells T, Ryan A, Crawford B, Evans C, et al. Neuropathic pain: A patient-centred approach to measuring outcomes. Health Expectations. 2018;21(4):774–786.
Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. Pain and Therapy. 2017;6(Suppl 1):25-33.
Binder A, Baron R. The pharmacological therapy of chronic neuropathic pain. Dtsch Arztebl Int. 2016 Set 16;113(37):616–625.
Brooks KG, Kessler TL. Treatments for neuropathic pain. Pharmaceutical Journal. 2017;9(12).
Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: From mechanisms to Treatment. Physiological Reviews. 2021 Ene 1;101(1):259–301.
Alles SRA, Smith PA. Etiology and pharmacology of neuropathic pain. Pharmacological Reviews. 2018 Abr;70(2):315–347.
Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review. Pain Med (United States). 2017 Oct 1;18(10):1999–2012.
Ogawa N, Terashima T, Oka K, Chan L, Kojima H. Gene therapy for neuropathic pain using dorsal root ganglion-targeted helper-dependent adenoviral vectors with GAD67 expression. Pain Reports. 2018;3(6):1–12.
García C. Fisiopatología del dolor neuropático. Actual Med. 2011;96(2011):45–59.
Sommer C, Leinders M, Üçeyler N. Inflammation in the pathophysiology of neuropathic pain. Pain. 2018 Mar 1;159(3):595–602.
Alcántara A, Ibor PJ, Trillo E, Verdugo A, Blanco E. Guías Clínicas. Dolor neuropático. Sociedad Española de Médicos de Atención Primaria; 2019.
Dai WL, Yan B, Bao YN, Fan JF, Liu JH. Suppression of peripheral NGF attenuates neuropathic pain induced by chronic constriction injury through the TAK1-MAPK/NF-κB signaling pathways. Cell Communication and Signaling. 2020;18(1):1–13.
Meacham K, Shepherd A, Mohapatra DP, Haroutounian S. Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr Pain Headache Rep. 2017 Jun;21(6):28.
Viswanath O, Urits I, Burns J, Charipova K, Gress K, McNally A et al. Central Neuropathic Mechanisms in Pain Signaling Pathways: Current Evidence and Recommendations. Adv Ther. 2020;37(5):1946–1959.
Zilliox LA. Neuropathic Pain. Continuum (Minneap Minn). 2017 Abr;23(2):512–532.
Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1–3):23–37.
Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 2004 Abr;108(3):237–247.
Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. Journal of Neuroscience. 2004;24(38):8232–8236.
Devor M. Sodium channels and mechanisms of neuropathic pain. Journal of Pain. 2006 Ene;7(1 Suppl.):S3-S12.
O’Connor AB, Dworkin RH. Treatment of Neuropathic Pain: An Overview of Recent Guidelines. American Journal of Medicine. 2009;122(10):S22–S32.
Bennett DLH. Informed drug choices for neuropathic pain. The Lancet Neurology. 2015;14(2):129–30.
Alba C, Llorca M, Mico JA, Berrocoso E. The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain. Pain. 2018 Dic;159(12):2606–2619.
Alcántara Montero A, Pacheco de Vasconcelos SR. Actualización en el abordaje diagnóstico y terapéutico del dolor neuropático desde atención primaria (II). Med Gen Fam. 2021 Mar 20;10(1):139–145.
Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Set;17(9):1113–1123.
Alcántara A, Sánchez C, Goicoechea C. Terapias emergentes en desarrollo clínico y nuevas aportaciones en dolor neuropático. Revista Española de Anestesiología y Reanimación. 2019;66(6):324–334.
Rey R. Treatment of neuropathic pain. Review of lasts guidelines and recommendations. Neurología Argentina. 2013;5 (1):1–7.
Doughty CT, Seyedsadjadi R. Approach to Peripheral Neuropathy for the Primary Care Clinician. Am J Med. 2018 Set;131(9):1010–1016.
Jones RCW, Lawson E, Backonja M. Managing Neuropathic Pain. Med Clin North Am. 2016 Ene;100(1): 151-167.
Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. Int J Mol Sci. 2017 Nov 21;18(11):2483.
Murphy D, Lester D, Clay Smither F, Balakhanlou E. Peripheral neuropathic pain. NeuroRehabilitation. 2020;47(3):265–283.
Lundbeck Institute. (2016). El mecanismo de acción de los antidepresivos tricíclicos (ADT). 2016. Lundbeck Institute Campus.
Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 Jun;96(6):399–409.
Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L et al. Beta(2) adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218–225.
Yalcin I, Tessier LH, Petit-Demoulière N, Waltisperger E, Hein L, Freund-Mercier MJ et al. Chronic treatment with agonists of beta(2)-adrenergic receptors in neuropathic pain. Exp Neurol. 2010;221(1):115–121.
Yalcin I, Tessier LH, Petit-Demoulière N, Doridot S, Hein L, Freund-Mercier MJ et al. Βeta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol Dis. 2009;33(3):386–394.
Onali P, Dedoni S, Olianas MC. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 2009;332(1):255–265.
Mu A, Weinberg E, Moulin D, Clarke H. Pharmacologic of Chronic Neuropathic Pain. Canadian Family Physician. 2017 Nov;63(11):844–852.
Jackson K. Pharmacotherapy for neuropathic pain. Pain Pract. 2006 Mar;6(1):27–33.
Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018 Jun;41(3):60–63.
Hiroki T, Suto T, Saito S, Obata H. Repeated Administration of Amitriptyline in Neuropathic Pain: Modulation of the Noradrenergic Descending Inhibitory System. Anesth Analg. 2017 Oct;125(4):1281–1288.
Valverde JA. Recomendaciones de tratamiento farmacológico del dolor neuropático. Neuroeje. 2012;25(2):51–61.
Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007 Dic;132(3):237–251.
Pliego LA. Inhibidores de la recaptación de serotonina y noradrenalina en el manejo del dolor de la neuropatía diabética. Neurología Argentina. 2010;2(3):180–188.
Bates D, Carsten Schultheis B, Hanes MC, Jolly SM, Chakravarthy K v., Deer TR et al. A Comprehensive Algorithm for Management of Neuropathic Pain. Pain Med (United States). 2019;20(Suppl 1):S2–S12.
Macone A, Otis J. Neuropathic Pain. Semin Neurol. 2018 Dic;38(6):544–653.
Caruso R, Ostuzzi G, Turrini G, Ballette F, Recla E, Dall’Olio R et al. Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis. Pain. 2019 Oct;160(10):2186–2198.
Vollert J, Magerl W, Baron R, Binder A, Enax-Krumova EK, Geisslingere G et al. Pathophysiological mechanisms of neuropathic pain: Comparison of sensory phenotypes in patients and human surrogate pain models. Pain. 2018 Jun. 159(6): 1090–1102.
Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015 Ago 23; 2015(8): CD011091.
Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech. 2012 Mar;13(1):125–133.
Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015 Abr;156(Suppl 1):S104–S114.
Lundbeck Institute. Los mecanismos de acción del inhibidor selectivo de la recaptación de serotonina y noradrenalina (ISRN). Dinamarca: Lundbeck Institute; 2016.
Casarotto MG, Craik DJ. Ring flexibility within tricyclic antidepressant drugs. J Pharm Sci. 2001;90(6):713–721.
Bergwerf H. Molview. MolView. Consultado el 16 marzo 2022. Disponible en:https://molview.org/
Moraczewski J, Aedma KK. Tricyclic Antidepressants. Estados Unidos: StatPearls; 2021.
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. 2007 Jul;151(6):737–748.
Marks DM, Shah MJ, Patkar AA, Masand PS, Park GY PCU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009 Dic;7(4):331–336.
Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014 Mar;11(3-4):37–42.
Chen Z, Yang J, Skolnick P. The design, synthesis and structure-activity relationship of mixed serotonin, norepinephrine and dopamine uptake inhibitors. Topics in Medicinal Chemistry. 2009;4:131–154.
Suwała J, Machowska M, Wiela-Hojeńska A. Venlafaxine pharmacogenetics: A comprehensive review. Pharmacogenomics. 2019 Jul;20(11):829–845.
Mahaney PE, Vu AT, McComas CC, Zhang P, Nogle LM, Watts WL et al. Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines. Bioorganic and Medicinal Chemistry. 2006 Dec 15;14(24):8455–8466.
Wright CL, Mist SD, Ross RL, Jones KD. Duloxetine for the treatment of fibromyalgia. Expert Rev Clin Immunol. 2010 Set;6(5):745–756.
Gálvez R, Ribera MV, Pérez C, Mico JA, Belenguer R, González M, et al. Guía de Práctica Clínica sobre el Tratamiento Farmacológico del Dolor Neuropático Periférico en Atención Primaria. Madrid: Master Line y Prodigio S.L.; 2016.
Gómez E. Dolor neuropático. Farmacia Abierta. 2015;29(2):31–35.
Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris). 2019;175(1–2):46–50.
Nishikawa N, Nomoto M. Management of neuropathic pain. J Gen Fam Med. 2017 Abr 12;18(2):56–60.
Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol. 2019 Nov 21;2019:8685954.
Markowltz JS, Patrick KS. Venlafaxine-tramadol similarities. Med Hypotheses. 1998 Ago;51(2):167–168.
Elmoheen A, Nazal AF, Zubaidi O, Siddiqui UA, Alhatou M. Expert review and recommendations for the management of acute, chronic, and neuropathic pain in Qatar. Qatar Med J. 2021 Jul;2021(2):1–16.
Van Velzen M, Dahan A, Niesters M. Neuropathic Pain: Challenges and Opportunities. Frontiers in Pain Research. 2020;1(August):1–4.
Bouhassira D, Attal N. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? Pain. 2018 Mar 1;159(3):576–582.
Alcántara A, Sánchez CI. Bloqueadores de los canales de sodio dependientes de voltaje: nuevas perspectivas en el tratamiento del dolor neuropático. Neurologia. 2021;36(2):169–171.
Di Stefano G, di Lionardo A, di Pietro G, Cruccu G, Truini A. Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis. Pain Research and Management. 2021 Abr 25;2021.
Keppel Hesselink JM, Schatman ME. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. J Pain Res. 2017 Feb 20;10:439–443.
Rice ASC, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet. 2014 May 10;383(9929):1637–1647.
Balogh M, Aguilar C, Nguyen NT, Shepherd AJ. Angiotensin receptors and neuropathic pain. Pain Rep. 2021 Mar 9;6(1):e869.
Bannwarth B, Kostine M. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer? Drugs. 2017 Set;77(13):1377–1387.
Comments
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.